Dr. Tina Q. Tan discusses the vaccine pipeline

From 2017-2018, antiviral treatment of hospitalized children with influenza ranged from 70%-86%. In the 2023-2024 season, it was less than 60%.

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

The initiation of a phase 2 study of the investigational 31-valent pneumococcal conjugate vaccine is expected by the end of January 2025.

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

Severe outcomes among children with pneumonia were uncommon, regardless of whether antibiotics were received based on study results.

"The novel RSV prevention strategies may reduce ICU morbidity and mortality for children," the study authors concluded.